Tackling Inequalities in Oral Health: Bone Augmentation in Dental Surgery through the 3D Printing of Poly(ε-caprolactone) Combined with 20% Tricalcium Phosphate

Personalized medicine and overcoming healthcare inequalities have gained significant popularity in recent years. Polymers offer an ideal solution due to their cost-effectiveness, ease of customized 3D printing, and potential for wide-scale expansion. Poly- mers blended with β-tricalcium phosphate (TCP) have been found to synergize with the environ- mental tissues of maxillary bones and promote osteoconductivity. However, little is known about their properties after printing and their ability to maintain their biological role; additionally, limi- tations exist in 3D printing when high TPC concentrations are added. Our study demonstrated that poly ε-caprolactone (PCL)+β-TCP 20% composite can be successfully printed and is a suitable ma- terial for commercial 3D printing. The material also demonstrated biocompatibility, supporting osteoblast adhesion and promoting cell proliferation and differentiation. The composite can also sustain ISO14937:200935 sterilization procedures, which makes it an ideal material for printing medical devices that can be used by clinicians worldwide.

The concept of personalized medicine and overcoming healthcare inequalities have become extremely popular in recent decades. Polymers can support cost reductions, the simplicity of customized printing processes, and possible future wide-scale expansion. Polymers with β-tricalcium phosphate (TCP) are well known for their synergy with oral tissues and their ability to induce osteoconductivity. However, poor information exists concerning their properties after the printing process and whether they can maintain an unaffected biological role. Poly(ε-caprolactone) (PCL) polymer and PCL compounded with TCP 20% composite were printed with a Prusa Mini-LCD-®3D printer. Samples were sterilised by immersion in a 2% peracetic acid solution. Sample analyses were performed using infrared-spectroscopy and statical mechanical tests. Biocompatibility tests, such as cell adhesion on the substrate, evaluations of the metabolic activity of viable cells on substrates, and F-actin labelling, followed by FilaQuant-Software were performed using a MC3T3-E1 pre-osteoblasts line. PCL+β-TCP-20% composite is satisfactory for commercial 3D printing and appears suitable to sustain an ISO14937:200937 sterilization procedure. In addition, the proper actin cytoskeleton rearrangement clearly shows their biocompatibility as well as their ability to favour osteoblast adhesion, which is a pivotal condition for cell proliferation and differentiation.